Page 2 of Attachment D 
This report contains recommendations relevant to operations at Cetus, Inc. 
Recommendations applicable to industries employing recombinant DMA tech- 
nology will be made after MI OSH completes a thorough assessment. An 
assessment of the following areas will be made: 
• process operations with attendant potentials 
for worker exposure 
• engineering controls (e.g., physical containment 
design, ventilation, exhaust gas filtration, waste 
product controls, etc.) 
• validation procedures (e.g., of sterilization, 
physical containment, and process termination) 
- work practices 
• emergency and accident procedures 
• .medical surveillance 
• environmental monitoring 
• numbers of exposed workers 
• employee training and education 
This survey of Cetus, Inc. in Berkeley, California was conducted as one 
of a series of initial walk-through surveys ox firms utilizing recombinant 
DUX techniques in research or production. 
DESCRIPTION OF THE COMPANY 
Cetus started in 1971 as an independent research organization. Cetus 
conducts’ research in genetic engineering, biochemistry, and molecular 
biology. Results of their research may then be developed, on a pilot 
plant scale, as technology adaptable for commercial application. Cetus 
plans to market this technology rather than manufacture the products 
the technology will produce. Research projects are generated fron 
within the company or in collaboration with other organizations. 
Cet us is currently conducting research in eighteen project areas. Approx- 
imately one-third of these projects involve recombinant DMA research and 
the remaining projects have the potential for recombinant DMA applications. 
Pharmaceutical research efforts include the application of recombinant DMA 
technology for the production of insulin and interferon. The largest part 
Of Cetus • research efforts are centered around organic chemical substitute 
fuel production. Resulting products of such research would be ethylene 
and propylene glycol and their oxides, ethanol, alkenes, and substitutes 
for lubricants and whale oil. Vaccines for animals and humans are also 
being developed. 
The Cetus Corporation is composed of five operating divisions . They are 
New Programs Development, Biochemical Research Development, Recombinant DMA 
Research«Group, Fermentation Process Development, and Station Screening 
and Strain Selection Research. These groups have overlapping responsibilities 
and a project nay receive the attention of each division. 
2 
[ 557 ] 
